Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice

Vaccine

Volumn 31, Issue 25, 2013, Pages 2778-2785

  Lévy, Camille ^a,b,c,d,e   Aerts, Laetitia ^f   Hamelin, Marie Ève ^f   Granier, Christelle ^a,b,c,d,e   Szécsi, Judit ^a,b,c,d,g   Lavillette, Dimitri ^a,b,c,d   Boivin, Guy ^f   Cosset, François Loïc ^a,b,c,d,e  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE LYON   (France)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Antibody; Metapneumovirus; Neutralization; Vaccine; Virus like particle

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN F; HUMAN METAPNEUMOVIRUS VACCINE; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; HUMAN METAPNEUMOVIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CROSS PROTECTION; GLYCOPROTEINS; HUMANS; IMMUNITY, HUMORAL; LUNG; METAPNEUMOVIRUS; MICE; MICE, INBRED BALB C; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL PROTEINS;

EID: 84878351256     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.051     Document Type: Article

References (38)

1. van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001, 7(June (6)):719-724.
2. Cane P.A., van den Hoogen B.G., Chakrabarti S., Fegan C.D., Osterhaus A.D. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003, 31(February (4)):309-310.
3. Pelletier G., Dery P., Abed Y., Boivin G. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002, 8(September (9)):976-978.
4. Williams J.V., Crowe J.E., Enriquez R., Minton P., Peebles R.S., Hamilton R.G., et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005, 192(October (7)):1149-1153.
5. Williams J.V., Martino R., Rabella N., Otegui M., Parody R., Heck J.M., et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005, 192(September (6)):1061-1065.
6. Williams J.V., Edwards K.M., Weinberg G.A., Griffin M.R., Hall C.B., Zhu Y., et al. Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis 2010, 201(June (12)):1890-1898.
7. Biacchesi S., Skiadopoulos M.H., Boivin G., Hanson C.T., Murphy B.R., Collins P.L., et al. Genetic diversity between human metapneumovirus subgroups. Virology 2003, 315(October (1)):1-9.
8. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Amaro-Carambot E., Surman S.R., Collins P.L., et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006, 345(February (2)):492-501.
9. Tang R.S., Mahmood K., Macphail M., Guzzetta J.M., Haller A.A., Liu H., et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine 2005, 23(February (14)):1657-1667.
10. Biacchesi S., Skiadopoulos M.H., Yang L., Lamirande E.W., Tran K.C., Murphy B.R., et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 2004, 78(December (23)):12877-12887.
11. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccines 2008, 4(January-February (1)):5-12.
12. Bellier B., Huret C., Miyalou M., Desjardins D., Frenkiel M.P., Despres P., et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27(September (42)):5772-5780.
13. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(April (9518)):1247-1255.
14. Szecsi J., Boson B., Johnsson P., Dupeyrot-Lacas P., Matrosovich M., Klenk H.D., et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 2006, 3:70.
15. Szecsi J., Gabriel G., Edfeldt G., Michelet M., Klenk H.D., Cosset F.L. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J Infect Dis 2009, 200(July (2)):181-190.
16. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011, 3(August (94)). 94ra71.
17. Dalba C., Bellier B., Kasahara N., Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 2007, 15(March (3)):457-466.
18. Hatziioannou T., Valsesia-Wittmann S., Russell S.J., Cosset F.L. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 1998, 72(June (6)):5313-5317.
19. Sandrin V., Boson B., Salmon P., Gay W., Negre D., Le Grand R., et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100(August (13)):823-832.
20. Sandrin V., Cosset F.L. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J Biol Chem 2006, 281(January (1)):528-542.
21. Hamelin M.E., Yim K., Kuhn K.H., Cragin R.P., Boukhvalova M., Blanco J.C., et al. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol 2005, 79(July (14)):8894-8903.
22. Hamelin M.E., Couture C., Sackett M.K., Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol 2007, 88(December (Pt 12)):3391-3400.
23. Garcia J.M., Lagarde N., Ma E.S., de Jong M.D., Peiris J.S. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol 2010, 47(January (1)):29-33.
24. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197(March (5)):633-642.
25. Cosset F.L., Marianneau P., Verney G., Gallais F., Tordo N., Pecheur E.I., et al. Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol 2009, 83(April (7)):3228-3237.
26. McGinnes L.W., Gravel K.A., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011, 85(January (1)):366-377.
27. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010, 84(January (2)):1110-1123.
28. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011, 204(October (7)):987-995.
29. Ryder A.B., Tollefson S.J., Podsiad A.B., Johnson J.E., Williams J.V. Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine 2010, 28(June (25)):4145-4152.
30. Mok H., Tollefson S.J., Podsiad A.B., Shepherd B.E., Polosukhin V.V., Johnston R.E., et al. An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. J Virol 2008, 82(November (22)):11410-11418.
31. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15(January (1)):34-41.
32. Okamoto M., Sugawara K., Takashita E., Muraki Y., Hongo S., Nishimura H., et al. Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults. J Med Virol 2010, 82(December (12)):2092-2096.
33. van den Hoogen B.G., Herfst S., de Graaf M., Sprong L., van Lavieren R., van Amerongen G., et al. Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 2007, 88(April (Pt 4)):1251-1259.
34. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Riggs J.M., Surman S.R., Amaro-Carambot E., et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004, 78(July (13)):6927-6937.
35. Herfst S., de Graaf M., Schrauwen E.J., Ulbrandt N.D., Barnes A.S., Senthil K., et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 2007, 88(October (Pt 10)):2702-2709.
36. Herfst S., Schrauwen E.J., de Graaf M., van Amerongen G., van den Hoogen B.G., de Swart R.L., et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008, 26(August (33)):4224-4230.
37. Cseke G., Wright D.W., Tollefson S.J., Johnson J.E., Crowe J.E., Williams J.V. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007, 81(January (2)):698-707.
38. Bellier B., Dalba C., Clerc B., Desjardins D., Drury R., Cosset F.L., et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24(March (14)):2643-2655.